Boston Scientific Corporation (NYSE:BSX)’s “Guidezilla” guiding PCI procedures

Posted by Samantha Donahue July 18, 2013 0 Comment 1541 views

Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S FDA was well as approval from CE mark for the Guide Extension Catheter “Guidezilla”. The device has been launched in the United States and in Europe. This device has been designed to make complicated PCI or percutaneous coronary intervention procedures easy by delivering interventional devices more efficiently. This includes devices such as stents and balloons and is great benefit in situations where additional back-up is necessitated.

Easing PCI procedures

The M.D of the Cardiac Catheterization Lab at the Barnes-Jewish hospital said that Guidezilla provides new levels of reassurance and confidence in the treatment of complex lesions. He is also the director of the Interventional Cardiology at Washington University, in St. Louis, Montana. He said that it can reduce the effort and the time that is required for numerous complex procedures.

The hypotube shaft is made of stainless steel and it offers kink resistance and pushability. The hydrophilic coating that the outer-diameter helps in reducing friction and makes it very easy for interventional cardiologists to navigate with ease and also access areas that are difficult to reach. The President Interventional Cardiology at Boston Scientific, Kevin Ballinger said that the company is committed to deliver various innovative technologies like “Guidezilla”. This device will help surgeons improve the outcomes for patients who are to undergo complicated coronary interventions.  Difficult lesions can be treated with ease with this new device.

Innovation to improve lives

Coronary artery disease is one of the leading causes of death in the United States. Guide extension catheters are used in various stenting and coronary angioplasty procedures that open up arteries that have been blocked by atherosclerosis. If affected arteries are left untreated, they have the potential to cause heart attack and angina. Boston Scientific has always found new and innovative methods of transforming lives through unique medical solutions that help in improving the health of patients across the globe.

About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment